CLDX Q3 2022 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$407,000+166.0% YoY

Gross Profit

-$21M-5200.2% margin

Operating Income

-$28M-6804.9% margin

Net Income

-$27M-6580.8% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

+149.7%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$36M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$369M

Total Liabilities

$24M

Stockholders' Equity

$345M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$407,000	$153,000	+166.0%
Gross Profit	-$21M	-$13M	-57.9%
Operating Income	-$28M	-$21M	-33.0%
Net Income	-$27M	-$20M	-31.0%

Revenue Segments

Contracts and grants

$407,000100%